InsiderDirector

Christopher Gibson Insider Trading Activity

Every SEC Form 4 transaction reported by Christopher Gibson, sourced directly from SEC EDGAR and updated as new filings are accepted.

By · Insider-trading data from SEC EDGAR
Latest filing:

Compiled automatically from SEC EDGAR Form 4 filings and refreshed daily. Figures count purchases (code P) and sales (code S) only — not grants, option exercises, or gifts. How this page is built. Not investment advice.

Quick Answer

Is Christopher Gibson buying or selling?

Christopher Gibson reported 0 open-market buys ($0) and 76 sells ($39.6M) across 76 Form 4 filings at 1 company — a net selling position of $39.6M.

Source: SEC EDGAR Form 4

What stands out

Key Statistics (as of Jun 5, 2026)

Total Form 4 filings
76
SEC EDGAR
Companies
1
Buys (0)
$0
Sells (76)
$39.6M

Insider sentiment

Net selling

Net insider flow of $39.6M in net selling, filed between Dec 10, 2021 – Jun 5, 2026.

Companies Christopher Gibson files for

#CompanyForm 4 filings
1RXRXRECURSION PHARMACEUTICALS, INC.76

Recent Christopher Gibson transactions

DateTickerRoleTypeSharesValueFiling
Jun 5, 2026RXRXDirectorSale40.0K$144.8KSEC ↗
May 27, 2026RXRXDirectorSale40.0K$123.2KSEC ↗
May 8, 2026RXRXDirectorSale40.0K$134.8KSEC ↗
Apr 24, 2026RXRXDirectorSale40.0K$144.4KSEC ↗
Apr 8, 2026RXRXDirectorSale40.0K$124.0KSEC ↗
Mar 25, 2026RXRXDirectorSale40.0K$130.0KSEC ↗
Feb 20, 2026RXRXDirectorSale40.0K$138.4KSEC ↗
Feb 6, 2026RXRXDirectorSale40.0K$164.8KSEC ↗
Jan 23, 2026RXRXDirectorSale40.0K$178.8KSEC ↗
Jan 7, 2026RXRXDirectorSale40.0K$170.0KSEC ↗
Dec 19, 2025RXRXChief Executive OfficerSale40.0K$180.0KSEC ↗
Dec 6, 2025RXRXChief Executive OfficerSale40.0K$185.2KSEC ↗
Nov 20, 2025RXRXChief Executive OfficerSale40.0K$166.4KSEC ↗
Nov 6, 2025RXRXChief Executive OfficerSale40.0K$208.4KSEC ↗
Oct 24, 2025RXRXChief Executive OfficerSale100.0K$570.0KSEC ↗
Oct 10, 2025RXRXChief Executive OfficerSale100.0K$604.0KSEC ↗
Sep 26, 2025RXRXChief Executive OfficerSale100.0K$476.0KSEC ↗
Sep 12, 2025RXRXChief Executive OfficerSale100.0K$471.0KSEC ↗
Aug 29, 2025RXRXChief Executive OfficerSale100.0K$484.0KSEC ↗
Aug 14, 2025RXRXChief Executive OfficerSale618.2K$3.3MSEC ↗
Mar 28, 2025RXRXChief Executive OfficerSale138.6K$837.0KSEC ↗
Mar 7, 2025RXRXChief Executive OfficerSale40.0K$259.0KSEC ↗
Feb 7, 2025RXRXChief Executive OfficerSale40.0K$316.0KSEC ↗
Jan 13, 2025RXRXChief Executive OfficerSale40.0K$287.2KSEC ↗
Dec 6, 2024RXRXChief Executive OfficerSale40.0K$285.6KSEC ↗

Showing the 25 most recent filings of 76. Screen every filing.

Christopher Gibson insider trading FAQ

Is Christopher Gibson buying or selling?

Across 76 SEC Form 4 filings, Christopher Gibson reported 0 open-market purchases totaling $0 and 76 sales totaling $39.6M — a net selling position of $39.6M.

Which companies does Christopher Gibson file Form 4s for?

Christopher Gibson has reported insider transactions at 1 company, most often RECURSION PHARMACEUTICALS, INC. (RXRX).

How far back does Christopher Gibson's filing history go?

Trabud holds Christopher Gibson's SEC Form 4 filings from Dec 10, 2021 – Jun 5, 2026, sourced directly from SEC EDGAR.

Where does Trabud get Christopher Gibson's insider trading data?

Directly from SEC EDGAR Form 4 filings. Every transaction on this page is a real filing accepted by the SEC, updated as new filings arrive.

Related Content

Learn

What is SEC Form 4?

The filing behind every transaction here

Guide

How to Track Insider Trading

A practical workflow for following Form 4 activity

Use Case

Insider Buying Signals

How investors read insider purchases

Track Christopher Gibson and every other insider

Screen all SEC Form 4 filings by insider, company, transaction value, and role — or ask Trabud's AI agent in plain English.

Open the screener